Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    IOFLUPANE I 123

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DATSCAN indication expanded to include use in patients with suspected DLB
    DATSCAN indication expanded to include use in patients with suspected DLB

    03 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221103005731/en

    BUSINESSWIRE
    03 Nov 2022
    Share Share
    Curium Announces FDA Approval of Generic Version of DaTscan in the U.S.
    Curium Announces FDA Approval of Generic Version of DaTscan in the U.S.

    05 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/05/2416189/0/en/Curium-Announces-FDA-Approval-of-a-Generic-Version-of-DaTscan-Ioflupane-I-123-Injection-in-the-U-S.html

    GLOBENEWSWIRE
    05 Apr 2022
    Share Share
    Curium's Generic Ioflupane Receives Approval in the U.S.
    Curium's Generic Ioflupane Receives Approval in the U.S.

    30 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213792

    FDA
    30 Mar 2022
    Share Share
    DEA Proposes to Remove Cocaine Derivative [123I]Ioflupane from Schedule II of the CSA – Almost Five Years after Receipt of HHS’s Recommendation
    DEA Proposes to Remove Cocaine Derivative [123I]Ioflupane from Schedule II of the CSA – Almost Five Years after Receipt of HHS’s Recommendation

    04 Jun 2015

    // Karla L. Palmer FDA LAW BLOG

    http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/06/dea-proposes-to-remove-cocaine-derivative-123iioflupane-from-schedule-ii-of-the-csa-almost-five-year.html

    Karla L. Palmer FDA LAW BLOG
    04 Jun 2015
    Share Share